MedTrace Logo

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

NCT00563992 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2012-05-01

No results posted yet for this study

Summary

This study will evaluate the effectiveness of two different mood stabilizing medications, lithium and valproate, in treating people with bipolar disorder and suicidal behavior.

Conditions

Interventions

DRUG

Lithium

Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.

DRUG

Valproic acid

Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Maria A. Oquendo, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2008-09-30
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563992 on ClinicalTrials.gov